REGENICS AT SCIENCE EVENTS

June 17-19th 2019

The Smart Patient. Regenics (CEO H.Lund co-chair)

Program 2019

December 15th 2018

DnB Healtcare Conference 2018

 

October 5-6th 2018

Wound Healing and Skin Diseaes, Los Angeles (CEO H.Lund keynote invitation)

June 19th – 20th 2018

Conference Biotech-Medtech-Expo, Stavanger (CEO H.Lund co-chair)

Program (tbd)

 

June 5-6th 2017

Investor Conference Biotech-Medtech, Stavanger (CEO co-chair)

Program (tbd)

March 9th 2017

Roundtable Conference in investing in Biotech, CEO Henrik Lund, moderator for the Event at Stavanger Forum Oslo

Program Roundtable Conference Stavanger

March 8th 2017

War on Cancer Nordics, CEO Henrik Lund in closing panel at the Economist Event in Oslo

Program Economist Event Oslo

December 15th 2016

DnB Healtcare Conference 2016, CMO Christian Clemm provides company update in the ventture session

Regenics presentation

October 19-20-21 2016

Biomarine Convention, CEO Henrik Lund, participating at Convention in Oslo

Program Biomarine Business Conference

October 19th 2016

DnB Next at Oslo Innovation Week, CSO Gry Lønne, presenting Regenics Company update in Oslo

program DNB Next healthcare Regenics presentation

September 25-28 2016

At the 4th Congress on Innovation in Drug Delivery in Antibes, Regenics presented abstract.

Abstract 4th Congress on Innovation in Drug Delivery

October 22-24 2015

Joint Meeting of the European Tissue Repair Society (ETRS) and the Wound Healing Society (WHS), Regenics presented abstract

Abstract 7th ETRS-WHS meeting

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.